Medicines planning
50 results
Applied filters
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 60mg biosimilars
21 November 2025Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
Annual medicines planning publication, Prescribing Outlook
20 October 2025Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
The licence and supporting evidence for aflibercept biosimilars
26 September 2025Aflibercept 2mg biosimilars Afqlir, Eydenzelt, Yesafili and Vgenfli are expected in December 2025 for NHS use. Learn about supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
19 September 2025We highlight evidence for licensed omalizumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Xolair).
Preparing to use omalizumab biosimilar
19 September 2025Omalizumab biosimilars are expected soon. We offer general information and implementation advice.